Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Suresh Senan(Amsterdam UMC Location VUmc), Marinus A. Paul(Amsterdam UMC Location VUmc), Reza J. Mehran(The University of Texas MD Anderson Cancer Center), Alexander V. Louie(Amsterdam UMC Location VUmc), Peter Balter(The University of Texas MD Anderson Cancer Center), Harry J.M. Groen(University Medical Center Groningen), Stephen E. McRae(The University of Texas MD Anderson Cancer Center), Joachim Widder(University Medical Center Groningen), Lei Feng(The University of Texas MD Anderson Cancer Center), Ben E.E.M. van den Borne(Catharina Ziekenhuis), Mark F. Munsell(The University of Texas MD Anderson Cancer Center), Coen Hurkmans(Catharina Ziekenhuis), Donald A. Berry(The University of Texas MD Anderson Cancer Center), Erik van Werkhoven(The Netherlands Cancer Institute), John J. Kresl(Phoenix (United States)), Anne‐Marie C. Dingemans(Maastricht University), Omar Thanoon Dawood(Bellevue Hospital Center), Cornelis J.A. Haasbeek(Amsterdam UMC Location VUmc), L.Steven Carpenter(Saint Luke's Health System), Katrien De Jaeger(Catharina Ziekenhuis), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Ben J. Slotman(Amsterdam UMC Location VUmc), Egbert F. Smit(Amsterdam UMC Location VUmc), Jack A. Roth(The University of Texas MD Anderson Cancer Center)
Cited by 1,459Open Access
Abstract
Related Papers
Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?
Hiroshi Onishi, Hiroki Shirato, Yasushi Nagata et al.|International Journal of Radiation Oncology*Biology*Physics|2010|614